Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in mice
Chronic use of mTORC1 inhibitors produces undesirable side effects in humans which limit their value for CNS disorders treatment. The authors present a binary drug strategy to protects mTORC1 activity in the periphery and show its potential utility in preclinical models of alcohol use disorder.
Guardado en:
Autores principales: | Yann Ehinger, Ziyang Zhang, Khanhky Phamluong, Drishti Soneja, Kevan M. Shokat, Dorit Ron |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7072a98d7a1d453daff66668b3c58af7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
por: Morris E Feldman, et al.
Publicado: (2009) -
mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation
por: Xiaolei Ding, et al.
Publicado: (2016) -
Crosstalks between mTORC1 and mTORC2 variagate cytokine signaling to control NK maturation and effector function
por: Fangjie Wang, et al.
Publicado: (2018) -
Differential controls of MAIT cell effector polarization by mTORC1/mTORC2 via integrating cytokine and costimulatory signals
por: Huishan Tao, et al.
Publicado: (2021) -
Regulation of colonic epithelial cell homeostasis by mTORC1
por: Takenori Kotani, et al.
Publicado: (2020)